Effectiveness of treatment of iron-deficiency anemia in infants and young children with ferrous bis-glycinate chelate.
Forty infants, 6 to 36 mo old, with iron-deficiency anemia (hemoglobin < 11 g/dL) were matched and assigned to two groups. One group received FeS0(4) and the other received ferrous bis-glycinate chelate at a dose of 5 mg of Fe daily per kilogram of body weight for 28 d. Both groups had significant hemoglobin increases (P < 0.001), but only the group treated with ferrous bis-glycinate chelate had significant increases (P < 0.005) in plasma ferritin. Apparent iron bioavailabilities were calculated at 26.7% for FeS0(4) and 90.9% for ferrous bis-glycinate chelate. Regression analysis indicated that absorption of both sources of iron were similarly regulated by the body according to changes in hemoglobin. We concluded that ferrous bis-glycinate chelate is the iron of choice for the treatment of infants with iron-deficiency anemia because of its high bioavailability and good regulation.
Pineda
O
O
Latin American Center for Nutrition and Metabolic Studies, Antigua, Guatemala.
Ashmead
H D
HD
D018798:Anemia, Iron-Deficiency / Q000188:drug therapy*; D001682:Biological Availability; D002675:Child, Preschool; D004311:Double-Blind Method; D005260:Female; D005293:Ferritins / Q000097:blood; D005296:Ferrous Compounds / Q000493:pharmacokinetics / Q000627:therapeutic use*; D005998:Glycine / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D007223:Infant; D007408:Intestinal Absorption; D007501:Iron / Q000097:blood / Q000493:pharmacokinetics; D007502:Iron Chelating Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D008297:Male; D012044:Regression Analysis; D016896:Treatment Outcome
D005296:Ferrous Compounds; D006454:Hemoglobins; D007502:Iron Chelating Agents; C073588:bis-glycino iron II; C020748:ferrous sulfate; D005293:Ferritins; D007501:Iron; D005998:Glycine